TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
25 women students to receive internship, training, and mentorship in Life Sciences segment
Subscribe To Our Newsletter & Stay Updated
